Tim O’Donnell

CTIM-10. PHASE 1 TRIAL OF PERSONALIZED NEOANTIGEN VACCINES IN COMBINATION WITH STANDARD CARE TO TREAT GLIOBLASTOMA

Cansu Cimen Bozkus, Julia Kodysh, Samantha Cheng, Alex Rubinsteyn et autres

Abstract The tumor microenvironment (TME) of glioblastoma (GBM) is populated by cells that foster immunosuppression. Reversing immunosuppression and promoting tumor surveillance by T cells that recognize the antigens generated by tumor-specific mutations (neoantigens) is critical to eliminating the tumor cells. In a …

us (code pays fourni par la source)

334 Phase I study of safety and activity of personalized neoantigen-based vaccines in combination with tumor treating fields for newly diagnosed glioblastoma patients

Julia Kodysh, Cansu Cimen Bozkus, Mansi Saxena, Marcia Meseck et autres

Background Glioblastoma (GBM) is one of the most aggressive and lethal cancers (median survival 15 months) characterized by a highly heterogeneous and immunosuppressive tumor microenvironment (TME). New treatments need to include innovative strategies that impact the TME, such as immunomodulation using neoantigen …

us (code pays fourni par la source)

Abstract CT173: PGV-001: A phase I trial of a multipeptide personalized neoantigen vaccine in the adjuvant setting

Julia Kodysh, Thomas U. Marron, Alex Rubinsteyn, Tim O’Donnell et autres

Abstract Background: Mutation-derived tumor antigens (MTAs) arise as a result of somatic mutations, such as nucleotide substitutions and small insertions/deletions. MTAs can serve as specific targets for antitumor therapy, including neoantigen vaccines. The goal of neoantigen vaccination is to help prime T …

us (code pays fourni par la source)

Immunology of COVID-19: Current State of the Science

Nicolas Vabret, Graham J. Britton, Conor Gruber, Samarth Hegde et autres

us (code pays fourni par la source)

Abstract B080: Improved neoantigen vaccine selection by combining prediction of pMHC presentation and T-cell epitopes

Julia Kodysh, Tim O’Donnell, Ana-Belén Blázquez, John P. Finnigan et autres

Abstract The OpenVax group has helped initiate two neoantigen vaccine clinical trials (NCT02721043, NCT02721043) at Mount Sinai based on a simple multiplicative ranking criterion which assigns equal weight to expression and predicted Class I MHC binding affinity of mutated peptides (1). This …

us (code pays fourni par la source)

Improved neoantigen vaccine selection by combining prediction of pMHC presentation and T-cell epitopes

Julia Kodysh, Tim O’Donnell, Ana-Belén Blázquez, Nina Bhardwaj et autres

We curated two datasets: (1) viral T cell epitopes from IEDB[1] and (2) mutated sequences and T cell responses from four neoantigen vaccine trials[2-5]. We used the viral dataset to several hypotheses related to features which are thought to predict T cell …

us (code pays fourni par la source)

Probing the increase in neoantigen burden at recurrence in ovarian cancer

Tim O’Donnell, Arun Ahuja, Alexandra Snyder, Jeff Hammerbacher

Somatic mutation burden correlates with response to checkpoint blockade immunotherapy [Van Allen 2015], raising the question of how it is affected by conventional chemotherapy. We explored changes in mutation burden in paired primary and chemotherapy-treated recurrence samples in 12 ovarian cancer patients …

us (code pays fourni par la source)

Heterogeneity of mutated tumor antigens in a single high grade ovarian serous carcinoma

Alex Rubinsteyn, John A. Martignetti, Elena Pereira, Tim O’Donnell et autres

us (code pays fourni par la source)